(J Clin Gastroenterol 2018;52:137-140) E radicating Helicobacter pylori continues to be a challenge for physicians, and no treatment regimen is uniformly successful in all treated patients. 1 There is good evidence that the efficacy of traditional first-line and second-line therapies is decreasing in most countries. 2 This is primarily due to the increasing prevalence of bacterial resistance for the available antibiotics. 3 Multidrug-resistant bacterial strains have emerged in other areas of the body, and H. pylori is no exception. The prevalence of H. pylori strains resistant to >1 antibiotic was found to be 15% in the United States and 8.9% in Europe. 3 In addition, H. pylori isolates exhibiting a resistance to 3 antibiotics (clarithromycin, metronidazole, and levofloxacin) are encountered frequently in clinical practice. We have previously reported that 4.8% of the treatment-naive and 37.7% of the previously treated patients are infected with strains resistant to 3 antibiotics. 4, 5 Both empiric and tailored therapy (based on culture and antibiotic sensitivity testing) are extremely difficult in these patients due to the paucity of effective agents. In addition, culture and antimicrobial sensitivity testing is not generally available in many parts of the world including the United States.
Rifabutin is a rifamycin derivative, which has very high bactericidal activity against H. pylori strains, and primary resistance against this drug is very low (< 2%). 3 Triple therapy with rifabutin and amoxicillin has been found to be a successful rescue therapy after consecutive treatment failures, and has yielded promising results in early studies of patients harboring resistant H. pylori strains. 5, 6 We therefore designed this study to test the efficacy of 12-day rifabutin-based triple therapy in a large number of patients infected with multidrug-resistant strains (3 antibiotics).
METHODS

Patients
Consecutive adult patients referred by their general practitioners to a single endoscopic unit for upper endoscopy due to dyspeptic symptoms after at least 1 therapy for H. pylori infection were considered for enrollment in the study. A standard 13 C-Urea Breath Test (UBT) was performed after an overnight fast in all patients. Infected patients were invited to undergo upper endoscopy for antibiotic susceptibility testing. Only patients infected with triple-resistant (clarithromycin, metronidazole, and levofloxacin) H. pylori strains were enrolled in this study. Exclusion criteria were as follows: (1) previous gastric surgery; (2) malignancy in the last 5 years; (3) severe comorbidities (hepatic, renal, cardiac failure); (4) known allergy toward penicillins or rifampycins; and (5) lack of delivering an informed consent to participate.
Bacterial Susceptibility Testing
All patients underwent upper endoscopy with standard biopsies performed according the updated OLGA staging. 7 Two additional biopsies were taken from the antrum for the bacterial culture and antibiotic susceptibility testing. These specimens were streaked immediately onto commercial selective medium Pylori Agar (BioMe´rieux Italia S.p.A., Bagno a Ripoli, Florence, Italy). The plates were incubated under microaerobic conditions at 371C for 72 hours. Once incubated, the colonies resembling H. pylori strains were identified by Gram stain and by oxidase, catalase, and urease tests. Suspensions from the primary plates were prepared in sterile saline solution to McFarland opacity standard 4 (approximately 108 cells/mL) to perform an ETest (AB Bio Disk, Solna, Sweden). An agar plate was streaked in 3 directions with a swab dipped into each bacterial suspension to produce a lawn of growth, and an ETest strip (E-Test) was placed on to a separate plate, which was incubated immediately in a microaerophilic atmosphere at 371C for 72 hours. Isolated strains were tested for primary clarithromycin, metronidazole, and levofloxacin resistance using break points for the minimal inhibitory concentration of >0.5, >8, and >1 mg/L, respectively, according to the updated recommendations of the European Committee on Antimicrobial Susceptibility Testing. 8 
Therapy Regimen
All patients received triple therapy with esomeprazole 40 mg bid, amoxicillin 1 g bid, and rifabutin 150 mg od for 12 days. All drugs were administered before breakfast and dinner. To enhance compliance, patients were instructed carefully to adhere to the drug regimen, after they had been given a written summary of the daily regimen. At the end of treatment, patients were invited for an office visit, where adherence to the therapy and the side-effect rate were assessed by a personal interview. In addition, a blood cell count was performed at the end of therapy in all patients. Good adherence was defined as >90% intake of the prescribed tablets. Empiric treatment was offered to patients who had unsuccessful eradication of H. pylori. These therapies were a repeat course of rifabutin-based therapy, concomitant therapy, or PPI plus 3-in-1 capsule, bismuthbased quadruple therapy (Pylera).
H. pylori Eradication Assessment
All patients underwent a standard UBT test 4 to 6 weeks after therapy ending. The UBT was performed after an overnight fast. A baseline breath sample was obtained, and 75 mg of 13 C urea with citric acid (1.5 g) was administered as an aqueous solution. Another breath sample was collected 30 minutes after the test solution was administered. H. pylori eradication was considered as achieved when delta over baseline values of 13 CO 2 were <4.5%, according to the manufacturer's recommendations. A UBT was performed when the patient took therapy for at least 7 days, whereas those who interrupted therapy earlier were considered as dropouts.
Statistical Analysis
Cure rates and their 95% confidence intervals (CI) were calculated at both intention-to-treat (ITT) analysis and per-protocol (PP) analysis. The ITT analysis included all the enrolled patients, whereas the PP analysis included only those patients who took >90% of their medications and completed the follow-up evaluation. Comparisons among patient subgroups were performed using the w 2 test, and the t test as appropriate. Multiple logistic regression was used to identify factors predicting H. pylori eradication. Odds ratios and 95% CI were calculated. A P-level <0.05 was considered significant. The SPSS software (version 19.0; SPSS Inc., Chicago, IL) was used for statistical computations.
RESULTS
A total of 257 out of 746 tested patients were found to be infected with a triple-resistant H. pylori strain after at least 1 antibiotic therapy course. Clinical and demographic characteristics are provided in Table 1 . All enrolled patients were included at ITT analysis, whereas 17 patients were lost to follow-up, and so the PP analysis included 240 patients. All patients reported good compliance with therapy. Overall, the infection was eradicated in 213 patients, corresponding to a cure rate of 82.9% (95% CI, 78.3-87.5) at ITT analysis and 88.7% (95% CI, 84.7-92.7) at PP analysis. As shown in Table 2 , at univariate analysis, the male gender was associated with a lower eradication rate than the female gender (80.6% vs. 92.3%, P = 0.009), whereas smoking, gastroduodenal disease, and the number of treatment failures did not affect the eradication rate. In addition, the mean age (52.3 ± 13.4 vs. 50.3 ± 14.2 y) and BMI values (25.1 ± 2.7 vs. 24.7 ± 3.8) did not differ significantly between successfully cured patients and those who failed eradication. At multivariate analysis, no factor emerged as an independent predictor of successful bacterial eradication (Table 3) .
A total of 44 (18.3%) patients complained of sideeffects, including nausea/vomiting (6 cases), abdominal pain (13 cases), mild diarrhea (12 cases), headache (4 cases), itching (4 cases), taste disturbance (4 cases), and myalgia (1 case). No case of leukopenia was observed in our series.
All the 27 patients who failed the eradication were invited to undergo an empiric retreatment with different regimens as there were no data in the literature to guide therapy in these patients. 9 Overall, 17 refused to be Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
retreated, 5 repeated the same rifabutin triple-regimen course, 4 patients received concomitant therapy because of rifabutin side-effects, and the last patient decided to take the new Pylera, which was available only outside Italy. The results are provided in Figure 1 .
DISCUSSION
Current European Guidelines for H. pylori infection management recommend that antibiotic susceptibility testing should be considered before second-line treatment if endoscopy is carried out for another reason, and carried out in all cases when a second-line treatment has failed. 10 In this study, we followed such an approach, and we specifically focused our attention on those patients who were infected with multiple-resistant H. pylori strains. The presence of antimicrobial-resistant strains of H. pylori to the 3 most commonly used antibiotics-that is, clarithromycin, metronidazole, and levofloxacin-reduces therapeutic options and therefore the success of any therapy considerably. Neither the US nor the European guidelines offer any empiric treatment solution for patients with multidrug-resistant strains of H. pylori. Rifabutin has been used as a rescue empiric therapy in patients with failure of >2 therapeutic attempts, 11 and as a culture-based approach in a few studies, 5 but there is little information on its efficacy and safety in a large cohort of patients infected with triple-resistant H. pylori strains. Our data showed 83% and near 90% eradication rates at ITT and PP analysis, respectively. This success rate is noteworthy as these patients would likely fail all conventional therapies. To our knowledge, 3 small studies have tested the efficacy of this low-dose rifabutin/high-dose proton pump inhibitor as the rescue therapy regimen, and all showed promising results. An 87.7% eradication rate was observed in our previous study, 5 whereas the cure rate was as high as 91% in an Australian study, 12 and 96% in a Korean study. 13 The high-dose proton pump inhibitor seems to play a major role. Indeed, a significantly higher eradication rate was achieved when double doses (lansoprazole 60 mg bid) were administered instead of standard doses (lansoprazole 30 mg bid) with the same rifabutin-amoxicillin combination. 13 Myelotoxicity and consequent neutropenia are potential side-effects of rifabutin therapy, particularly with high dosages and prolonged therapy. 14 Lower doses and/or a shorter duration would make this side-effect less likely. Indeed, incidence rates as high as 1.5%, 15 2%, 16 20%, 17 and 25% 18 were observed when 300 mg rifabutin were administered for 10 days, whereas when the same dose was given for 7 days, neutropenia occurred in 0% to 1.8% of the cases. 19, 20 In the present study, we used a 150 mg dose and no case of neutropenia was observed in a large cohort of patients. Following the same low dose, no leukopenia occurred in a study with 129 patients, 12 and only 1 (0.9%) case occurred in another study with 105 patients. 5 Therefore, a 12-day 150-mg rifabutin regimen appears to be better tolerated than the 300-mg regimens, although the clinical significance of such a transient neutropenia is questionable.
The development of multidrug-resistant strains of H. pylori mirrors trends seen with other infections. A number of superbugs such as methicillin-resistant Staphylococcus aureus and the ESKAPE organisms (an acronym for Enterococcus faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and enterobacter species) have multidrug resistance as an important characteristic of their superbug status. 21 Rifabutin is being evaluated for use as a primary treatment for H. pylori in patients with uninvestigated dyspepsia in the United Stares. 22 In conclusion, there is no current standard for the growing population of patients with multidrug-resistant strains of H. pylori. The 12-day, low-dose rifabutin/highdose proton pump inhibitor regimen is a safe and reliable 
